

Appendix 1. The relationship between demographic data and changes of erectile function at baseline and the end of the study (month 6)

		Baseline		Month 6		Difference (month 6 - baseline)	
		B (95% CI)	p.	B (95% CI)	p.	B (95% CI)	p.
Age		-0.411 (-0.491,-0.332)	<0.001	-0.388 (-0.502,-0.274)	<0.001	-0.198 (-0.473,0.077)	0.155
Length of marriage		-0.073 (-0.393,0.248)	0.653	0.053 (-0.288,0.393)	0.760	0.153 (-0.091,0.397)	0.216
Education level Ref.= (Postgraduate)	Illiterate	-4.413 (-9.655,0.830)	0.098	-4.049 (-7.823,-0.276)	0.036	-0.244 (-4.494,4.006)	0.909
	Primary/high school	-3.866 (-7.791,0.58)	0.053	-2.957 (-6.962,1.048)	0.146	1.271 (-1.594,4.135)	0.380
	Undergraduate	-1.845 (-5.765,2.076)	0.352	-2.241 (-5.865,1.382)	0.222	-0.330 (-2.921,2.262)	0.801
Place of residence; Ref.=(village)	City	0.251 (-3.778,4.280)	0.902	0.280 (-4.558,5.117)	0.909	-2.044 (-5.504,1.417)	0.244
Vaccination status; Ref.= (Non-vaccinated)	One dose	2.00 (-10.22,14.22)	0.746	6.00 (-7.273,19.27)	0.372	4.00 (-2.577,10.577)	0.230
	2 doses	0.457 (-5.048,5.961)	0.870	2.587 (-3.392,8.566)	0.392	2.130 (-0.832,5.093)	0.157
	3 doses	-2.568 (-8.191,3.055)	0.367	-3.518 (-5.915, 1.121)	0.129	0.703 (-2.324,3.729)	0.646
Type of vaccine Ref.= (Not-vaccinated)	Sinopharm BIBP	2.888 (-2.655,5.121)	0.418	2.561 (-3.391,8.513)	0.395	1.585 (-1.391,4.562)	0.293
	AstraZeneca Covishield	0.375 (-7.019,7.769)	0.920	4.125 (-3.879,12.12)	0.309	3.750 (-0.253,7.753)	0.066
	Shifa Pharmmed COVIran Barekat	-7.667 (-17.92,2.594)	0.141	-10.33 (-21.44,0.775)	0.068	-2.667 (-8.222,2.888)	0.343
	Other	-2.727 (-8.354,2.899)	0.338	-1.364 (-7.455,4.728)	0.658	1.364 (-1.682,4.410)	0.376
Comorbidity; Ref.=(Yes)		0.423 (-0.520,1.367)	0.375	0.412 (-0.615,1.439)	0.427	-0.194 (-0.928,0.541)	0.601

Appendix 2. The relationship between demographic data and changes of orgasmic function at baseline and the end of the study (month 6)

		Baseline		Month 6		Difference (month 6 - baseline)	
		B (95% CI)	p.	B (95% CI)	p.	B (95% CI)	p.
Age		-0.033 (-0.198,-0.015)	0.003	-0.131 (-0.175,-0.088)	<0.001	-0.056 (-0.089,-0.024)	0.001
Length of marriage		-0.089 (-0.119,-0.060)	<0.001	0.018 (-0.111,0.148)	0.777	0.073 (-0.054,0.200)	0.254
Education level Ref.= (Postgraduate)	Illiterate	-1.480 (-3.827,0.867)	0.214	-1.736 (-3.994,0.522)	0.130	0.601 (-1.607,2.809)	0.590
	Primary/high school	-1.550 (-3.217,0.118)	0.068	-1.164 (-2.686,0.358)	0.132	0.271 (-1.217,1.759)	0.718
	Undergraduate	-0.604 (-2.111,0.904)	0.429	-0.811 (-2.188,0.565)	0.245	-0.509 (-1.855,0.837)	0.454
Place of residence; Ref.=(village)	City	0.374 (-1.432,2.180)	0.682	-0.438 (-2.276,1.400)	0.673	-1.726 (-3.524,0.071)	0.060
Vaccination status; Ref.= (Non-vaccinated)	One dose	1.900 (-2.491,6.291)	0.392	1.700 (-2.995,6.395)	0.474	-0.200 (-3.783,3.383)	0.912
	2 doses	0.400 (-1.578,2.378)	0.689	0.874 (-1.241,2.989)	0.414	0.474 (-1.140,2.088)	0.561
	3 doses	-0.384 (-2.404,1.637)	0.707	-0.773 (-2.933,1.387)	0.479	-0.389 (-2.038,1.259)	0.640
Type of vaccine Ref.= (Not-vaccinated)	Sinopharm BIBP	0.693 (-1.288,2.674)	0.489	0.834 (-1.281,2.949)	0.435	0.141 (-1.501,1.784)	0.865
	AstraZeneca Covishield	0.400 (-2.264,3.064)	0.766	1.325 (-1.520,4.170)	0.357	0.925 (-1.284,3.134)	0.408
	Shifa Pharmed COVIran Barekat	-1.933 (-5.631,1.764)	0.302	-3.467 (-7.415,0.481)	0.084	-1.533 (-4.599,1.532)	0.323
	Other	-0.539 (-2.567,1.488)	0.598	-0.588 (-2.753,1.577)	0.591	-0.048 (-1.730,1.633)	0.954
	Comorbidity; Ref.=(Yes)	0.082 (-0.341,0.505)	0.701	0.150 (-0.240,0.540)	0.447	-0.017 (-0.399,0.356)	0.930

Appendix 3. The relationship between demographic data and changes of sexual desire function at baseline and the end of the study (month 6)

		Baseline		Month 6		Difference (month 6 - baseline)	
		B (95% CI)	p.	B (95% CI)	p.	B (95% CI)	p.
Age		-0.094 (-0.115,-0.072)	<0.001	-0.108 (-0.139,-0.077)	<0.001	-0.065 (-0.171,0.042)	0.231
Length of marriage		-0.025 (-0.092,0.042)	0.465	0.023 (-0.068,0.114)	0.615	0.046 (-0.048,0.141)	0.331
Education level Ref.= (Postgraduate)	Illiterate	-0.984 (-1.864,-0.105)	0.029	-1.852 (-3.443,-0.261)	0.023	-1.044 (-2.688,0.600)	0.210
	Primary/high school	-0.754 (-1.481,-0.027)	0.042	-0.883 (-1.956,0.189)	0.105	-0.238 (-1.346,0.869)	0.670
	Undergraduate	-0.723 (-1.404,-0.042)	0.038	-0.542 (-1.512,0.428)	0.270	0.153 (-0.849,1.155)	0.762
Place of residence; Ref.=(village)	City	-0.434 (-1.270,0.401)	0.304	0.455 (-0.840,1.750)	0.487	0.649 (-0.689,1.987)	0.338
Vaccination status; Ref.= (Non-vaccinated)	One dose	-0.700 (-3.629,2.229)	0.636	0.800 (-2.889,4.489)	0.668	1.50 (-1.044,4.044)	0.245
	2 doses	0.039 (-1.280,1.359)	0.953	0.691 (-0.971,2.353)	0.411	0.652 (-0.494,1.798)	0.261
	3 doses	-0.457 (-1.804,0.891)	0.503	-0.511 (-2.208,1.187)	0.552	-0.054 (-1.255,1.117)	0.927
Type of vaccine Ref.= (Not-vaccinated)	Sinopharm BIBP	0.007 (-1.319,1.333)	0.991	0.715 (-0.928,2.357)	0.390	0.707 (-0.438,1.852)	0.223
	AstraZeneca Covishield	0.050 (-1.734,1.834)	0.956	1.175 (-1.034,3.384)	0.293	1.125 (-0.415,2.665)	0.150
	Shifa Pharmed COVIran Barekat	-2.033 (-4.509,0.442)	0.106	-2.700 (-5.765,0.365)	0.084	-0.667 (-2.803,1.470)	0.537
	Other	-0.336 (-1.694,1.021)	0.624	-0.488 (-2.169,1.193)	0.566	-0.152 (-1.323,1.020)	0.798
	Comorbidity; Ref.=(Yes)	-0.029 (-0.255,0.167)	0.769	0.210 (-0.065,0.485)	0.132	0.236 (-0.048,0.520)	0.103

Appendix 4. The relationship between demographic data and changes of intercourse satisfaction at baseline and the end of the study (month 6)

		Baseline		Month 6		Difference (month 6 - baseline)	
		B (95% CI)	p.	B (95% CI)	p.	B (95% CI)	p.
Age		-0.179 (-0.224,-0.134)	<0.001	-0.177 (-0.230,-0.125)	<0.001	-0.048 (-0.183,0.087)	0.484
Length of marriage		-0.051 (-0.191,0.089)	0.469	-0.008 (-0.163,0.147)	0.919	0.041 (-0.079,0.161)	0.502
Education level Ref.= (Postgraduate)	Illiterate	-1.906 (-3.723,-0.088)	0.040	-2.717 (-4.806,-0.627)	0.011	-0.153 (-2.245,1.939)	0.885
	Primary/high school	-2.338 (-3.840,-0.836)	0.003	-1.630 (-3.361,0.102)	0.065	0.782 (-0.628,2.192)	0.273
	Undergraduate	-0.880 (-2.287,0.527)	0.217	-1.270 (-2.870,0.330)	0.118	-0.321 (-1.596,0.955)	0.618
Place of residence; Ref.=(village)	City	-0.437 (-2.171,1.297)	0.618	0.090 (-2.110,2.290)	0.935	-0.174 (-1.877,1.529)	0.839
Vaccination status; Ref.= (Non-vaccinated)	One dose	0.300 (-5.466,6.066)	0.918	0.400 (-5.635,6.435)	0.896	0.100 (-3.094,3.294)	0.951
	2 doses	0.648 (-1.950,3.245)	0.621	0.661 (-2.058,3.379)	0.630	0.013 (-1.426,1.452)	0.986
	3 doses	-0.524 (-3.178,2.129)	0.696	-1.316 (-4.093,1.461)	0.349	-0.792 (-2.261,0.678)	0.287
Type of vaccine Ref.= (Not-vaccinated)	Sinopharm BIBP	0.751 (-1.860,3.363)	0.569	0.632 (-2.069,3.333)	0.643	-0.120 (-1.564,1.325)	0.870
	AstraZeneca Covishield	0.550 (-2.962,4.062)	0.756	1.150 (-2.483,4.783)	0.531	0.600 (-1.343,2.543)	0.541
	Shifa Pharmed COVIran Barekat	-2.867 (-7.741,2.008)	0.246	-5.100 (-10.14,0.059)	0.053	-2.233 (-4.930,0.463)	0.103
	Other	-0.473 (-3.146,2.200)	0.726	-1.130 (-3.895,1.634)	0.419	-0.658 (-2.136,0.821)	0.379
	Comorbidity; Ref.=(Yes)	0.057 (-0.349,0.463)	0.781	0.274 (-0.193,0.741)	0.246	0.184 (-0.178,0.545)	0.315

Appendix 5. The relationship between demographic data and changes of overall satisfaction at baseline and the end of the study (month 6)

		Baseline		Month 6		Difference (month 6 - baseline)	
		B (95% CI)	p.	B (95% CI)	p.	B (95% CI)	p.
Age		-0.009 (-0.082,-0.022)	0.016	-0.073 (-0.102,-0.045)	<0.001	-0.105 (-0.232,0.021)	0.101
Length of marriage		-0.050 (-0.073,-0.027)	<0.001	0.037 (-0.047,0.120)	0.387	0.086 (-0.026,0.198)	0.129
Education level Ref.= (Postgraduate)	Illiterate	-1.998 (-3.279,-0.718)	0.003	-1.551 (-2.684,-0.418)	0.008	0.136 (-1.816,2.088)	0.890
	Primary/high school	-1.649 (-2.532,-0.767)	<0.001	-1.326 (-2.265,-0.387)	0.006	0.280 (-1.035,1.596)	0.673
	Undergraduate	-1.136 (-1.951,-0.320)	0.007	-1.023 (-1.891,-0.156)	0.021	0.024 (-1.166,1.215)	0.968
Place of residence; Ref.=(village)	City	1.959 (0.973,2.945)	<0.001	0.626 (-0.562,1.814)	0.298	-1.741 (-3.330,-0.151)	0.032
Vaccination status; Ref.= (Non-vaccinated)	One dose	-0.100 (-2.754,2.554)	0.941	1.00 (-1.934,3.934)	0.500	1.100 (-2.067,4.267)	0.492
	2 doses	-0.122 (-1.317,1.074)	0.840	0.370 (-0.952,1.691)	0.370	0.491 (-0.935,1.918)	0.496
	3 doses	-0.695 (-1.916,0.527)	0.262	-0.419 (-1.769,0.931)	0.539	0.276 (-1.181,1.733)	0.708
Type of vaccine Ref.= (Not-vaccinated)	Sinopharm BIBP	-0.222 (-1.428,0.984)	0.716	0.402 (-0.934,1.739)	0.551	0.624 (-0.812,2.061)	0.390
	AstraZeneca Covishield	0.400 (-1.222,2.022)	0.625	0.500 (-1.298,2.298)	0.582	0.100 (-1.832,2.032)	0.918
	Shifa Pharmed COVIran Barekat	-0.100 (-2.351,2.151)	0.930	-1.167 (-3.661,1.328)	0.355	-1.067 (-3.747,1.614)	0.431
	Other	-0.767 (-2.001,0.468)	0.220	-0.409 (-1.777,0.959)	0.554	0.358 (-1.112,1.827)	0.630
	Comorbidity; Ref.=(Yes)	-0.047 (-0.282,0.187)	0.691	0.015 (-0.238,0.267)	0.909	0.044 (-0.293,0.382)	0.794